Harnessing the full potential of induced proximity therapeutics
Magnet Biomedicine’s modular TrueGlue™ Platform enables the systematic discovery of molecular glues for the treatment of human disease. Our monovalent molecular glue inhibitors (MGIs) represent an emerging class of induced proximity medicines with the potential to transform treatment across multiple therapeutic areas.
Science & Technology
What is a molecular glue inhibitor?
Molecular glue inhibitors (MGIs) are orally administered small-molecule therapeutics that induce proximity between a disease-relevant target and a Presenter protein, leading to Presenter-dependent target inhibition.
This approach offers the potential to create a new generation of safer, more effective oral medicines for immune disorders and tumor-targeted therapies for cancer.
Magnet's MGIs have the potential to address even the most intractable targets while offering several distinct advantages.
- Broad target reach – MGIs can address hard-to-drug proteins in both intracellular and extracellular environments.
- Ligand-independent discovery – MGIs do not require a known ligand for the target protein, opening opportunities beyond traditionally druggable targets.
- Target specificity – MGIs can achieve highly selective target inhibition, including discrimination between single-point mutant and wild-type proteins.
- Presenter dependency – Strategic Presenter selection can confer tissue- or cell-type specificity and introduce complementary biology.
- Cooperative pharmacology – Cooperative ternary-complex formation can drive potent activity without the hook effect associated with bifunctional molecules.
Our platform has enabled the discovery of multiple Presenter proteins, including a proprietary Super Presenter that has unlocked access to a range of hard-to-drug extracellular targets in immunology and inflammation.
Magnet's TrueGlue™ platform enables rational selection of protein pairs and systematic discovery of MGIs to achieve unprecedented therapeutic goals.
We integrate state-of-the-art screening technologies, proprietary chemical libraries, generative AI, and the strategic selection of Target and Presenter proteins to systematically discover MGIs.
Our Pipeline
Magnet's innovative induced proximity pipeline spans I&I and oncology.
Magnet's portfolio is driven by a multipronged strategy to unlock novel therapeutics for hard-to-drug targets across immunology and oncology while delivering the convenience of orally administered medicines.
Our proprietary Super Presenter has enabled the discovery of potent, selective MGIs against immunology and inflammation targets that have traditionally been inaccessible to oral small molecules. The use of the Super Presenter allows MGIs to easily access body tissues and makes them well suited as therapeutics for a broad spectrum of illnesses across both common and rare immune and oncology diseases.
Presenter
Program
Indications
Early Discovery
Lead Op
Phase 1
Super Presenter
ST2
COPD, asthma
Super Presenter
TL1A
Multiple
Super Presenter
Undisclosed
Multiple
Oncology Presenter 1
ONCOLOGY
PROGRAM 1
PROGRAM 1
Undisclosed
Early Discovery
Partnered with
Oncology Presenter 2
ONCOLOGY
PROGRAM 2
PROGRAM 2
Undisclosed
Early Discovery
Partnered with
Oncology Presenter 3
ONCOLOGY
PROGRAM 3
PROGRAM 3
Undisclosed
Early Discovery
Partnered with
OUR PEOPLE
Magnet's team combines decades of drug development experience.
Our diverse scientific expertise pushes the boundaries of existing technologies to advance a new era of precision induced proximity medicines for diseases with high unmet need, including autoimmune diseases and cancer.
- All
- Leadership
- Team
- Founders
- Board Of Directors
- Scientific Advisory Board
Brian Safina, PhD
President & Chief Executive Officer
Nick Vlahakis, MBBS
Chief Medical Officer
Bharat Reddy, PhD
Chief Business Officer
Bret Williams, PhD
Senior Vice President of Research
Matthew Hayward, PhD
Vice President of Drug Discovery
Jennifer Franklin
Vice President of Operations
Mabel Lee, MBA
Vice President of Portfolio & Program Management
Rajesh Menon, MBA
Vice President, Clinical Operations
Stefanie Johns, PhD
VP, Regulatory Affairs
Kristina Burow
Managing Director at ARCH Venture Partners
Thomas Cahill, MD, PhD
Founder and Managing Partner at Newpath Partners
Seiji Miyahara, PhD
Partner & Senior Investment Director at Taiho Ventures
Jay Parrish, PhD
Venture Partner at ARCH Venture Partners Chairman and CEO at Pretzel Therapeutics
Jordan Zwick
Venture Partner at ARCH Venture Partners and the Co-Founder and CBO of Mirador Therapeutics
Ramnik Xavier, MD, PhD
Scientific Advisory Board Chair
Benjamin F. Cravatt, PhD
Founder & Advisor
David A. Spiegel, MD, PhD
Founder & Advisor
Michael Rosbash, PhD
Founder & Advisor
Richa Saxena, PhD
Founder & Advisor
Stuart Schreiber, PhD
Founder & Advisor
Douglas Beshore, PhD
Chemistry
Austin Carr, PhD
Proteomics
Gina Chen
Chemistry
Xiao Chen, PhD
Biology
YiQun Chen
Biology
Jessica Gasser, PhD
Biology
Nastaran Gerami-Moayed
Biology
Adarsh Godbole
Biology
Kara Herlihy
Biology
Yuan Hu, PhD
Chemistry
Bruce Hua, PhD
Chemistry
Liam Hudson, PhD
Chemistry
Anita Kim
Lab Operations
Chueh-Ling Kuo, PhD
Biology
Jason Lowe, PhD
Chemistry
Alyssa Lutservitz, MS
Chemistry
Jessica McManus
Biology
James Ralff
Chemistry
Andrew Reidenbach, PhD
Biology
Olivia Sierra
Biology
Anthony Scruse, PhD
Chemistry
Danielle Thibault
Office Manager
Luke Stamatakis, CPA
Finance & Accounting
Tom Tian, PhD
Biology
Tiffany Tsang, PhD
Biology
Go Watanabe, PhD
Biology
Hsin-Lan Wen, PhD
Biology
Kevin Wielenberg, PhD
Chemistry
Olivia Zhang, PhD
Biology
CAREERS
Magnet Biomedicine is building a world-class team to unleash the scientific breakthroughs and expertise of our founders.
We are looking for creative, thoughtful, science-first innovators to join our collaborative team. Come help us realize the potential of molecular glues to achieve the broadest possible impact for patients.
Director/Senior Director, Translational Immunology
Senior Scientist, Computational Chemistry
Senior Administrative Assistant, Research & Clinical Operations
